Home > Publications Database > Interneuronal In Vivo Transfer of Synaptic Proteins. > print

001     256448
005     20240403131748.0
024 7 _ |a 10.3390/cells12040569
|2 doi
024 7 _ |a pmid:36831238
|2 pmid
024 7 _ |a pmc:PMC9954582
|2 pmc
024 7 _ |a altmetric:142978988
|2 altmetric
037 _ _ |a DZNE-2023-00310
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Klinkenberg, Michael
|0 P:(DE-2719)2810845
|b 0
|e First author
245 _ _ |a Interneuronal In Vivo Transfer of Synaptic Proteins.
260 _ _ |a Basel
|c 2023
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711373188_22709
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a Neuron-to-neuron transfer of pathogenic α-synuclein species is a mechanism of likely relevance to Parkinson's disease development. Experimentally, interneuronal α-synuclein spreading from the low brainstem toward higher brain regions can be reproduced by the administration of AAV vectors encoding for α-synuclein into the mouse vagus nerve. The aim of this study was to determine whether α-synuclein's spreading ability is shared by other proteins. Given α-synuclein synaptic localization, experiments involved intravagal injections of AAVs encoding for other synaptic proteins, β-synuclein, VAMP2, or SNAP25. Administration of AAV-VAMP2 or AAV-SNAP25 caused robust transduction of either of the proteins in the dorsal medulla oblongata but was not followed by interneuronal VAMP2 or SNAP25 transfer and caudo-rostral spreading. In contrast, AAV-mediated β-synuclein overexpression triggered its spreading to more frontal brain regions. The aggregate formation was investigated as a potential mechanism involved in protein spreading, and consistent with this hypothesis, results showed that overexpression of β-synuclein, but not VAMP2 or SNAP25, in the dorsal medulla oblongata was associated with pronounced protein aggregation. Data indicate that interneuronal protein transfer is not a mere consequence of increased expression or synaptic localization. It is rather promoted by structural/functional characteristics of synuclein proteins that likely include their tendency to form aggregate species.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a animal models
|2 Other
650 _ 7 |a oligomerization
|2 Other
650 _ 7 |a protein spreading
|2 Other
650 _ 7 |a vagus nerve
|2 Other
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a beta-Synuclein
|2 NLM Chemicals
650 _ 7 |a Vesicle-Associated Membrane Protein 2
|2 NLM Chemicals
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a alpha-Synuclein: metabolism
|2 MeSH
650 _ 2 |a beta-Synuclein: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain Stem: pathology
|2 MeSH
650 _ 2 |a Vesicle-Associated Membrane Protein 2: metabolism
|2 MeSH
700 1 _ |a Helwig, Michael
|0 P:(DE-2719)2810665
|b 1
|u dzne
700 1 _ |a Pinto-Costa, Rita
|0 P:(DE-2719)9001609
|b 2
|u dzne
700 1 _ |a Rollar, Angela
|0 P:(DE-2719)2812656
|b 3
|u dzne
700 1 _ |a Rusconi, Raffaella
|0 P:(DE-2719)2810495
|b 4
|u dzne
700 1 _ |a Di Monte, Donato A
|0 P:(DE-2719)2481741
|b 5
|u dzne
700 1 _ |a Ulusoy, Ayse
|0 P:(DE-2719)2772760
|b 6
|e Last author
|u dzne
770 _ _ |a Alpha-Synuclein Pathology in Human Diseases
773 _ _ |a 10.3390/cells12040569
|g Vol. 12, no. 4, p. 569 -
|0 PERI:(DE-600)2661518-6
|n 4
|p 569
|t Cells
|v 12
|y 2023
|x 2073-4409
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/256448/files/DZNE-2023-00310.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/256448/files/DZNE-2023-00310.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:256448
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810845
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810665
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001609
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812656
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810495
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2481741
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2772760
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-01-07T08:42:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELLS-BASEL : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-08-01T15:15:06Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-08-01T15:15:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-30
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELLS-BASEL : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-08-01T15:15:06Z
920 1 _ |0 I:(DE-2719)1013008
|k AG Di Monte
|l Neurodegeneration and Neuroprotection in Parkinson´s Disease
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013008
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21